Characteristic | Number of patients | Percentagea | DC-SCRIPTb (reference-normalized), × 102 | |
---|---|---|---|---|
All patients | 1,505 | 100% | 0.69 | 0.73 |
Age, years | ||||
≤ 40 | 192 | 13% | 0.69 | 0.72 |
41-55 | 561 | 37% | 0.70 | 0.74 |
56-70 | 498 | 33% | 0.70 | 0.77 |
>70 | 254 | 17% | 0.64 | 0.64 |
P = 0.15c | ||||
Menopausal status | ||||
Premenopausal | 637 | 42% | 0.72 | 0.74 |
Postmenopausal | 868 | 58% | 0.66 | 0.70 |
P = 0.06d | ||||
Grade | ||||
Poor | 818 | 54% | 0.64 | 0.74 |
Unknown | 452 | 30% | 0.71 | 0.68 |
Moderate and good | 235 | 16% | 0.80 | 0.70 |
P = 0.001e | ||||
Tumor size | ||||
pT1, ≤ 2 cm | 517 | 34% | 0.81 | 0.84 |
>2 cm | 988 | 66% | 0.63 | 0.64 |
P < 0.001d | ||||
Lymph nodes involved | ||||
No | 837 | 56% | 0.69 | 0.73 |
Yes | 668 | 44% | 0.68 | 0.75 |
P = 0.64d | ||||
ESR1 mRNA statusf | ||||
Positive, ≥0.2 | 1,176 | 78% | 0.71 | 0.73 |
Negative, < 0.2 | 329 | 22% | 0.61 | 0.66 |
P = 0.004c | ||||
PGR mRNA statusf | ||||
Positive, ≥0.1 | 949 | 63% | 0.72 | 0.74 |
Negative, < 0.1 | 556 | 37% | 0.61 | 0.66 |
P < 0.001c | ||||
ESR2 mRNA statusf | ||||
Dichotomized high, ≥0.005 | 741 | 49% | 0.89 | 0.95 |
Dichotomized low, < 0.005 | 742 | 49% | 0.54 | 0.49 |
P < 0.001c | ||||
Invasive tumor cell contentg | ||||
≥70% | 719 | 48% | 0.57 | 0.51 |
< 70% | 786 | 52% | 0.85 | 0.91 |
P < 0.001d | ||||
Histological type | ||||
DCIS + IDC | 194 | 13% | 0.82 | 0.89 |
ILC | 135 | 9% | 0.81 | 0.94 |
IDC | 810 | 54% | 0.66 | 0.69 |
Mucinous | 40 | 3% | 0.56 | 0.65 |
Medullary | 31 | 2% | 0.69 | 1.18 |
P = 0.012e | ||||
Intrinsic breast cancer subtypeh | 308 | |||
Normal-like | 22 | 7% | 1.43 | 1.19 |
ERBB2+ | 63 | 20% | 0.75 | 0.68 |
Luminal A | 76 | 25% | 0.78 | 0.89 |
Luminal B | 65 | 21% | 0.56 | 0.36 |
Basal | 82 | 27% | 0.48 | 0.48 |
P < 0.001e |